www.tickerreport.com ·
spectral ai q1 earnings call highlights
Topic context
This topic has been covered 353816 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSpectral AI is a medical device company focused on AI-powered burn assessment. The commercial mechanism is weak: the company is pre-revenue for its core product (DeepView), with FDA clearance and commercialization still pending. The $31.7 million BARDA funding supports development but does not yet translate to product revenue. No immediate price, margin, or supply chain impact on any sector. The primary affected product is the DeepView system for burn assessment, but no scarcity or supply chain disruption is evident. The impact is single-company-specific and early-stage.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Spectral AI reported a net loss of $3.4 million in Q1 2026, down from net income of $2.9 million in Q1 2025.
- R&D revenue declined to $4.0 million due to completion of a federal contract.
- Company submitted De Novo application for DeepView burn assessment system in June 2025, expects FDA response by end of Q2 2026.
- Received $31.7 million in BARDA funding to support DeepView development.
- Delivered handheld device prototype to MTEC; plans to bid for Phase III contract.
DeepView's FDA decision expected to create mild sector attention; impact remains flat.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- MEDICAL_DEVICESmid
